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Data from observational studies1–6 and clinical trials of lipid-
lowering therapy7–10 have provided reliable evidence regarding
the importance of serum cholesterol level as a determinant of
coronary heart disease (CHD) risk in mainly Caucasian popu-
lations from Europe, North America, Australia, or New Zealand.
This has resulted in widespread efforts to reduce population
levels of cholesterol, as well as to treat individuals at high risk
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Background Cholesterol levels in many Asian countries are rising. Predictions of the likely
effects of this on the incidence of cardiovascular diseases have mostly relied on
data from Western populations. Whether the associations between total cholesterol
and cardiovascular diseases are similar in Asia is not established.
Methods The Asia Pacific Cohort Studies Collaboration (APCSC) is an individual-participant
data meta-analysis of prospective studies from the Asia-Pacific region. Cox models
were applied to the combined data from 29 cohorts to estimate the region-, sex-,
and age-specific hazard ratios of major cardiovascular diseases by the fifths of
total cholesterol.
Results At baseline, the age/sex-adjusted mean value of total cholesterol was higher 
in Australia and New Zealand (ANZ) (5.52 ± 1.05 mmol/l) than in Asia 
(4.87 ± 1.05 mmol/l). During 2 million person-years of follow-up among 352 033
individuals, 4841 cardiovascular deaths were recorded. The association of total
cholesterol with coronary heart disease and stroke was similar in Asian and 
ANZ cohorts. Overall, each 1-mmol/l higher level of total cholesterol was
associated with 35% (95% CI: 26–44%) increased risk of coronary death, 25%
(95% CI: 13–40%) increased risk of fatal or non-fatal ischaemic stroke, and 20%
(95% CI: 8–30%) decreased risk of fatal haemorrhagic stroke.
Conclusions In both Asian and non-Asian populations in the Asia-Pacific region, total
cholesterol is similarly strongly associated with the risk of CHD and ischaemic, but
not haemorrhagic, stroke. Rising population-wide levels of cholesterol would be
expected to contribute to a substantial increase in the overall burden of cardio-
vascular diseases in this region.
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of CHD with lipid-lowering drugs. The associations between
cholesterol level and the risk of stroke are less clear; in par-
ticular, concerns remain regarding a possible inverse association
between cholesterol levels and the risk of intracerebral
haemorrhage.11–13
The Asia-Pacific region currently accounts for approximately
half the global burden of cardiovascular diseases, and future
projections suggest this proportion will increase.14,15 Particu-
larly in Eastern Asia, cholesterol levels and the incidence of
CHD are lower than in most Caucasian populations, while the
incidence of stroke is higher, and includes a greater proportion
of haemorrhagic stroke.16–19 However, there are data which indi-
cate that population-wide levels of adverse risk factors,
including cholesterol, are rising substantially in many countries
in Asia.20,21 To date, predictions on future disease burden as a
consequence of this have relied on knowledge of the associ-
ations between risk factors and atherothrombotic diseases in
Western populations. Very few such data are available from
Asia, and precise population-specific estimates of the nature and
magnitude of the associations between risk factors and
cardiovascular diseases in the region are lacking.
The Asia Pacific Cohort Studies Collaboration (APCSC) is an
individual-participant data overview of prospective cohort studies
conducted in a number of Asian countries, Australia, and New
Zealand. With several thousand events recorded, the Collabor-
ation provides a unique opportunity to produce reliable evidence
regarding the nature and size of the associations between risk
factors and cardiovascular diseases, and to compare these associ-
ations between Asian and non-Asian populations. In this report,
we describe the results relating to total cholesterol, and estimate
the likely effects of rising population-wide levels of cholesterol
on the burden of CHD and stroke in this region.
Methods
Participating studies
The design of the APCSC, an overview (meta-analysis) of pro-
spective observational studies, has been described elsewhere.22
Study eligibility criteria included being based in the Asia-Pacific
region, and having at least 5000 person-years of follow-up.
Studies were excluded if the study population was selected on
the basis of the presence of any disease or risk factor. In this
paper, only those studies with baseline measures of total
cholesterol are included. Studies were classified as Asian if their
participants were recruited from China, Japan, Korea, or South
East Asia, or from ‘ANZ’ if their participants were recruited from
Australia or New Zealand. Definitions of region were based only
on the geographical location of the cohort, and not on the
ethnic origin of individual participants.
Measurement of baseline variables
Total cholesterol was measured at baseline in 25 of the 37 studies
included in the APCSC database at the end of 2001. Of these
studies, seven (five in Asia and two in ANZ) also obtained repeat
cholesterol measurements on up to seven occasions. Cholesterol
measurements were determined using serum samples, and
these were obtained while fasting in approximately 93% of
participants. As these studies were initiated over a long period
of time (1966–1994), the methods and instruments used for
measuring cholesterol varied. Information regarding method of
cholesterol analysis was available from 15 studies comprising
68% of all participants; amongst these, 96% of cholesterol levels
were determined using enzymatic methods. In each study, age,
sex, and blood pressure at baseline were recorded. Wherever
available, baseline body mass index (BMI), smoking status,
alcohol consumption, and the presence or absence of diabetes
were also recorded.
Outcomes
All studies reported deaths by underlying cause; a subset of
studies also reported non-fatal cardiovascular disease events.
Outcomes were classified according to the Ninth Revision of the
International Classification of Diseases (ICD-9). The fatal out-
comes considered in this analysis were: CHD (ICD-9: 410–414);
total stroke (430–438); haemorrhagic stroke (431.0–432.9); and
ischaemic stroke (433.0–434.9). Two composite outcomes were
also considered: death due to CHD or non-fatal myocardial
infarction (MI), and fatal or non-fatal stroke. Since most studies
used record linkage with official sources, verification of strokes
was not routinely reported. However, 9 of the 25 studies included
in this analysis provided information on stroke verification; in
these 9 studies, stroke sub-type was determined on the basis of
imaging, lumbar puncture or autopsy in 515 of 606 cases (85%).
Statistical methods
All analyses used individual-participant data, and were restricted
to individuals aged 20 years at the time of the baseline survey.
To assess the association of ‘usual’ cholesterol level with the
outcomes of interest, baseline cholesterol measurements were
adjusted to account for regression dilution bias.23,24 Repeat
measurements of cholesterol were obtained from approximately
7% of participants between 1 and 18 years following the base-
line measurement. These repeat measures were used to estimate
regression dilution attenuation coefficients, using a linear mixed
regression model that accounted for the heterogeneity of vari-
ance between studies, within-subject correlation, and the varying
time intervals between measurements. The attenuation coef-
ficients derived by this method were similar for men and women,
and between age groups, but differed significantly between
regions. Thus, region-specific attenuation coefficients24 were
used for all separate analyses in Asian (2.30) and in ANZ (1.60)
populations, while the overall population coefficient (1.70) was
used for all other analyses.
For grouped analyses, individuals were classified according to
approximately equal fifths of baseline cholesterol for the entire
study population (4.1, 4.2–4.6, 4.7–5.1, 5.2–5.8, and 
5.9 mmol/l). Trends in mean values of other major continu-
ous cardiovascular risk factors across these fifths were assessed
through simple linear regression, coding the groups in rank
order. Trends in percentages for binary risk factors were assessed
similarly using χ2 tests for trend.25 Cox proportional hazards
regression models were used to estimate hazard ratios (HR), with
corresponding 95% CI calculated using the ‘floating absolute risk’
method in order to provide a CI for the reference group.26 Log-
linearity of cholesterol associations was explored through the
analysis of fifths of cholesterol, and summarized through the HR
and 95% CI for a 1-mmol/l increase in usual cholesterol.
All analyses reported here were stratified by study and sex,
and adjusted for time-dependent age at risk, systolic blood
pressure, and smoking status. For the subset of participants in
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whom baseline data on diabetes status, alcohol consumption,
and BMI were available, further adjustment was made for these
variables. However, these additional adjustments had very little
effect and so are not reported here.
Results
The 29 cohorts from 25 studies in the APCSC with data on
baseline cholesterol are summarized in Table 1. The analyses
included 352 033 individuals with almost 2 million person-
years of follow-up, which represented 83% of the entire APCSC
study population. The mean age of participants at baseline was
47 years, and 42% were women. Compared with participants in
the ANZ studies, the Asian cohort tended to be younger (46 years
versus 51 years) and be represented by fewer women (40%
versus 52%).
The distribution of baseline cholesterol levels for the Asian
and ANZ participants respectively is shown in Figure 1. The age-
and sex-adjusted mean cholesterol value for ANZ participants
was 5.52 mmol/l (95% CI: 5.51–5.53 mmol/l), and 4.87 mmol/l
(95% CI: 4.86–4.88 mmol/l) for Asian participants. The mean
cholesterol value was similar in men (4.80 mmol/l, 95% 
CI: 4.79–4.81) and women (4.82 mmol/l, 95% CI: 4.82–4.83).
The age- and sex-adjusted levels of major cardiovascular risk
factors within study population fifths of baseline cholesterol are
summarized in Table 2. Age, systolic blood pressure, BMI, the
prevalence of current alcohol consumption, and diabetes all
increased with increasing total cholesterol, but smoking preva-
lence was unrelated to cholesterol levels.
CHOLESTEROL, CHD, AND STROKE IN THE ASIA PACIFIC REGION 565
Table 1 Major characteristics of studies
No. of Cholesterol, mean (sd) Women Mean age Median follow-up
Study name subjects (mmol/l) % (years) (years)
Aito Town 1672 4.62 (0.85) 56.6 51.0 15.2
Akabane 1826 4.98 (0.92) 55.8 54.0 11.0
Anzhen 02 4141 4.72 (0.87) 51.0 47.0 3.0
Capital Iron and Steel Company 4772 4.83 (1.00) 0.0 45.3 12.5
Civil Serivce Workers 9303 5.19 (0.92) 33.1 46.7 6.7
Fangshan 815 4.58 (1.05) 66.9 46.9 2.7
Hisayama 1539 4.07 (0.95) 56.5 54.0 24.6
Hong Kong 194 5.26 (0.96) 52.1 79.0 2.5
Huashan 1595 4.66 (0.89) 54.4 52.9 2.9
KMIC 183 216 4.94 (0.98) 37.0 44.1 5.5
Kounan Town 1220 4.88 (0.87) 55.3 51.8 6.4
Miyama 414 5.11 (0.89) 62.1 59.2 6.6
Ohasama 1907 5.00 (0.87) 64.8 58.2 4.1
Saitama 3623 5.00 (0.87) 62.2 54.5 10.3
Seven Cities 17 999 4.87 (1.28) 55.3 56.1 2.7
Shanghai Factory Workers 8997 4.16 (0.86) 31.0 48.4 14.0
Shibata 2319 4.63 (1.20) 57.6 56.8 20.0
Shigaraki 3748 5.00 (0.90) 59.6 57.2 4.4
Shirakawa 4634 4.63 (0.90) 54.3 48.0 17.5
Singapore 92 3330 5.35 (1.05) 51.7 38.8 6.2
Six Chinese 14 483 4.19 (0.92) 48.5 45.0 8.4
Tanno/Soubetsu 1968 4.94 (0.92) 53.4 51.1 16.4
CVDFACTS 5522 4.97 (1.16) 55.5 47.1 6.0
Xi’an 1686 4.61 (0.90) 33.8 44.4 19.5
Yunnan Tin Miner 2621 4.31 (0.78) 4.0 54.3 4.5
Sub-Total Asia 283 544 4.86 (1.02) 40.3 46.2 5.5
Busselton 7401 5.87 (1.28) 52.1 45.3 20.5
Fletcher Challenge 10 224 5.36 (1.15) 27.9 44.4 4.8
Melbourne Cancer 41 137 5.53 (1.05) 58.9 54.8 5.6
Perth 9727 5.78 (1.22) 47.3 45.4 14.4
Sub-Total ANZa 68 489 5.58 (1.13) 51.9 50.9 5.7
Total 352 033 5.00 (1.09) 42.52 47.1 5.5
a Australia and New Zealand.
Figure 1 Distribution of baseline cholesterol among participants in
Asian and Australia and New Zealand (ANZ) cohorts
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Outcomes
During follow-up, 4841 (34%) of all deaths were assigned an
underlying cardiovascular cause (Table 3). Of these, 1889 deaths
were due to stroke (1529 in Asia, 360 in ANZ), and 1737 were
due to coronary disease (654 in Asia, 1083 in ANZ). In Asian
cohorts, stroke and coronary disease accounted for 51% and
566 INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
Table 2 Distribution of major risk factors by baseline cholesterol fifth, adjusted by age and sex
Fifth of cholesterol
Variables No.a 1 (4.1 mmol/l) 2 (4.2–4.6 mmol/l) 3 (4.7–5.1 mmol/l) 4 (5.2–5.8 mmol/l) 5 (5.9 mmol/l) P-valueb
Mean & 95% CI
Age (years) 352 033 45.2 (45.1–45.2) 45.6 (45.6–45.7) 46.5 (46.4–46.6) 48.0 (47.9–48.0) 50.4 (50.3–50.4) 0.0001
Body mass index
(kg/m2) 337 838 22.4 (22.40–22.45) 23.00 (22.97–23.02) 23.37 (23.34–23.39) 23.93 (23.90–23.95) 24.72 (24.69–24.74) 0.0001
Systolic blood 
pressure (mmHg) 352 033 122.4 (122.2–122.5) 123.6 (123.4–123.7) 124.6 (124.5–124.8) 126.2 (126.1–126.3) 129.3 (129.2–129.4) 0.0001
Percentage & 95% CI
Current smoking 327 854 38.3 (37.8–38.8) 36.4 (35.9–36.9) 36.3 (35.8–36.7) 36.0 (35.4–36.5) 36.7 (36.2–37.1) 0.38
Current alcohol 
consumption 307 998 43.7 (43.2–44.3) 49.1 (48.5–49.7) 51.2 (50.7–51.8) 53.6 (53.0–54.2) 56.4 (55.8–57.0) 0.0001
History of diabetes 123 605 2.1 (1.9–2.4) 2.7 (2.5–2.9) 3.0 (2.8–3.3) 3.1 (2.9–3.4) 3.5 (3.3–3.7) 0.0001
a No. of participants with data available for each variable.
b P-value for linear trend across the fifths.
Table 3 Cardiovascular events
No. of Deaths Fatal or non-fatal events
a
Study name subjects CVDb Stroke Haem.c Isch.d U/K-Se CHDf Stroke Haem. Isch. U/K-S MIg
Aito Town 1672 55 24 5 0 19 15
Akabane 1826 36 12 1 9 2 7 38 5 16 17 28
Anzhen 02 4141 2 1 1 0 0 1 16 14 2 1
Capital Iron and Steel Company 4772 109 69 47 16 6 40 165 64 92 9 82
Civil Service Workers 9303 13 2 1 0 1 1
Fangshan 815 2 1 0 0 1 0 8 2 5 1 2
Hisayama 1539 287 168 50 93 25 50 313 62 221 30 85
Hong Kong 194 15 4 0 0 4 7
Huashan 1595 13 6 3 3 0 3 16 6 10 0 3
KMIC 183 216 566 287 144 14 129 127 331 331 141
Kounan Town 1220 26 13 3 2 8 3
Miyama 414 1 0 0 0 0 0
Ohasama 1907 16 5 2 0 3 4 42 10 27 5
Saitama 3623 120 55 15 27 13 24
Seven Cities 17 999 337 123 87 30 6 62 220 119 99 2
Shanghai Factory Workers 8997 373 249 0 0 249 81
Shibata 2319 338 202 36 74 92 66
Shigaraki 3748 29 13 2 1 10 3
Shirakawa 4634 162 72 28 28 16 44 87 30 39 18 64
Singapore 92 3330 33 6 2 2 2 22 44 5 14 25 33
Six Chinese 14483 215 87 61 16 10 19 131 65 56 10 31
Tanno/Soubetsu 1968 72 33 16 10 7 23 93 16 10 67 23
CVDFACTS 5522 59 29 8 7 14 12
Xi’an 1686 80 41 24 15 2 35
Yunnan Tin Miner 2621 55 27 23 4 0 5
Sub-Total Asia 283 544 3014 1529 559 351 619 654 1504 384 603 517 493
Busselton 7401 1170 253 32 42 179 668 641 57 127 457 973
Fletcher Challenge 10224 108 16 1 1 14 68 98 6 19 73 127
Melbourne Cancer 41137 254 32 12 5 15 161
Perth 9727 295 59 10 4 45 186
Sub-Total ANZh 68 489 1827 360 55 52 253 1083 739 63 146 530 1100
Total 352 033 4841 1889 614 403 872 1737 2243 447 749 1047 1593
a Only studies that reported both fatal and non-fatal outcomes contributed events to this combined endpoint.
b Cardiovascular disease
c Haemorrhagic stroke.
d Ischaemic stroke.
e Stroke of unknown type or subarachnoid haemorrhage.
f Coronary heart disease.
g Myocardial infarction.
h Australia and New Zealand.
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22% of cardiovascular deaths respectively; in ANZ cohorts,
stroke caused 20%, and coronary disease 59%, of cardiovascular
deaths. Non-fatal events were recorded in 15 studies for stroke
(1436 events), and 13 studies for MI (716 events). Subclas-
sification into ischaemic or haemorrhagic stroke was provided
for only 54% and 51% of all fatal and non-fatal strokes
respectively. Of those strokes classified, 44% in Asia and 35% in
ANZ were haemorrhagic.
Cholesterol and risk of coronary heart disease
There was a continuous, positive association between usual
cholesterol levels and the risk of CHD, which persisted after
adjustment for age, sex, blood pressure, and smoking. For each
1-mmol higher than usual cholesterol level, the risk of coronary
death was approximately 35% (95% CI: 26–44%) greater (Figure
2A), while the risk of the combined outcome of non-fatal MI or
coronary death was 45% (95% CI: 35–55%) higher (Figure 2B).
The HR for coronary death associated with a 0.7-mmol/l increase
in usual cholesterol (the mean difference between Asian and
ANZ cohort values) was 1.23 (95% CI: 1.18–1.29). The
association between usual cholesterol and CHD was similar in
ANZ and Asia (Figures 2C and 2D), and there was no evidence
of heterogeneity by age or sex (Figure 3). Exclusion of the
studies contributing most events in each region (the Korean
Medical Insurance Corporation (KMIC) study with ~20% of
fatal coronary events in Asia, and the Busselton Study with
~70% of fatal coronary events in ANZ) did not materially alter
the point estimates of association.
Cholesterol and risk of stroke
Overall, no association between usual cholesterol and risk of
fatal stroke was observed (Figure 4A). However, when the com-
bined outcome of fatal or non-fatal stroke was considered, weak
evidence of a positive log-linear association emerged (Figure 4B).
Each 1-mmol/l higher level of cholesterol was associated with 
a 7% (95% CI: 0.9–14%) greater risk of fatal or non-fatal
stroke. When compared with those in the lowest fifth of usual
cholesterol level, the risk of fatal or non-fatal stroke among
individuals belonging to the highest fifth was increased by about
20% (HR = 1.2, 95% CI: 1.1–1.3). Significant heterogeneity 
(P = 0.03) between Asia and ANZ was observed for the associ-
ation between cholesterol and fatal stroke (Figure 4C). This
CHOLESTEROL, CHD, AND STROKE IN THE ASIA PACIFIC REGION 567
Figure 2 Association between usual cholesterol level and coronary heart disease (CHD): A—death due to
CHD in the entire study population; B—death due to CHD or non-fatal myocardial infarction (MI) in the
entire study population; C—death due to CHD stratified by region; D—death due to CHD or non-fatal MI
stratified by region. In Figures 2C and 2D, the hazard ratio for the lowest fifth of cholesterol is fixed at 1.0
separately for Asia and Australia and New Zealand (ANZ). P-values for test of homogeneity are shown. The
number of events within each fifth of cholesterol is shown separately for Asia and ANZ below Figures 2C and
2D. Analyses are stratified by study and sex, and adjusted for age at risk, systolic blood pressure, and smoking
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heterogeneity appears to reflect an unusually low risk associated
with the lowest fifth of cholesterol in ANZ; the HR remained
approximately constant over the other cholesterol fifths. There
was no evidence of any regional difference in the association
between usual cholesterol levels and risk of the composite
outcome of fatal or non-fatal stroke (Figure 4D). Again, repeat
analysis after exclusion of KMIC in Asia and the Busselton
study in ANZ resulted in similar estimates of the association
between cholesterol and stroke.
There were substantial differences in the relationship between
cholesterol and the risks of ischaemic and haemorrhagic stroke.
While there was the appearance of a positive association
between cholesterol and the risk of fatal ischaemic stroke
(Figure 5A), this was not statistically significant. However, each
1-mmol/l higher level of usual cholesterol was associated with
a 25% (95% CI: 13–40%) greater risk of fatal or non-fatal
ischaemic stroke (Figure 5B). When compared with the lowest
fifth of usual cholesterol levels, the risk for this combined out-
come was about 50% higher for those belonging to the highest
fifth (hazard ratio = 1.5, 95% CI: 1.3–1.8).
In contrast, there was evidence of an inverse association
between usual cholesterol levels and risk of death due to haem-
orrhagic stroke (Figure 5C). The test for log-linearity was signifi-
cant; each 1-mmol/l higher value of cholesterol was associated
with a 20% (95% CI: 8–30%) lower risk of haemorrhagic
stroke death. The HR for haemorrhagic stroke death associated
with a 0.7-mmol/l increase in usual cholesterol (the mean
difference between Asian and ANZ cohort values was 0.86
[95% CI: 0.78–0.94]). However, the excess risk appears to be
mostly confined to those below the second quintile of cholesterol
(5.0 mmol/l). There were fewer studies and fewer events
included in the analysis of the composite endpoint of fatal or
non-fatal haemorrhagic stroke; for this outcome no definite
association with cholesterol levels was observed (Figure 5D).
Discussion
These data confirm a strong, positive, and continuous log-linear
association between usual serum cholesterol levels and the risk
of developing CHD. In terms of stroke risk, we found evidence
of an association with cholesterol for the combined fatal and
non-fatal outcome, but not for fatal stroke alone. There was a
significant positive association between cholesterol and the risk
of fatal or non-fatal ischaemic stroke, and a weaker negative
association between cholesterol and the risk of fatal haem-
orrhagic stroke.
Aside from providing unique data involving Asian cohorts,
the APCSC has many other advantages. The combination of data
from numerous cohorts results in a large number of events, thus
providing precise estimates of association. The use of individual-
participant data and the availability of repeat cholesterol
measures in a number of cohorts also provides the opportunity
to limit systematic error due to regression dilution bias. We
found that the use of population-specific attenuation factors to
correct the effects of regression dilution bias had a substantial
effect on our estimates of association, while adjustment for
major confounding variables had relatively little effect. The
calculated attenuation factor for Asia was higher than that for
ANZ; this probably reflects greater variation in measurement
error in determining cholesterol levels in Asia. Another import-
ant potential for bias resides in misclassification of events,
particularly with respect to stroke subtype. Reliable verification
of subtype requires imaging or autopsy data, and while it is
likely that such information formed the basis of most reporting,
this could not always be confirmed.
Numerous other observational studies, particularly in men,
have demonstrated a strong, continuous, graded, and inde-
pendent association between cholesterol and the risk of CHD.1–6
The current data clearly extend these findings to Asian popu-
lations with substantially lower average levels of cholesterol, and
confirm that effects are similar in men and women.
568 INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
Figure 3 Association between usual cholesterol level and death due
to coronary heart disease (CHD) and non-fatal myocardial infarction
(MI), stratified by: A—gender; B—age at baseline. The hazard ratio for
the lowest fifth of cholesterol is fixed at 1.0 for men in Figure 3A, and
in the group aged 60–74 years in Figure 3B. P-values for test of homogeneity
are shown. The number of events within each fifth of cholesterol is
shown beneath each Figure. Analyses are stratified by study and sex,
and adjusted for age at risk, systolic blood pressure, and smoking
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Unlike CHD, the relationship between cholesterol level and
the risk of stroke is complex. The APCSC data suggest that the
lack of association between cholesterol and the overall risk of
fatal stroke is due to a positive association between cholesterol
and ischaemic stroke, partially counter-balanced by a weaker
negative association between cholesterol and haemorrhagic
stroke. The association with ischaemic stroke appears stronger
and more conclusive; the lack of association for the endpoint of
fatal stroke is likely explained by a higher case-fatality rate
associated with haemorrhagic stroke,27 and thus disproportion-
ate representation of this stroke sub-type among fatal outcomes.
This is consistent with the finding of a positive association
between cholesterol and total stroke risk when both fatal and
non-fatal events are considered. Furthermore, the 1.5:1.0 ratio of
non-fatal to fatal stroke observed in the current analysis (based
only on those cohorts that reported both fatal and non-fatal
outcomes) is somewhat lower than that expected from
surveillance data.28 This is consistent with underreporting of
non-fatal events (which are more likely to be ischaemic), and
may have resulted in underestimation of the true association
between cholesterol and total stroke. Again, we did not find any
clear evidence of regional differences in any of these associations.
Other observational data have variably demonstrated a weak
positive or a lack of any association between cholesterol levels
and the risk of stroke.12,13,29–36 However, most studies were
conducted in Caucasian populations at relatively low risk of stroke,
and thus with limited power to detect moderate yet meaningful
associations, and many failed to examine associations with stroke
sub-types. Some studies have reported clear evidence of a positive
log-linear association between cholesterol and the risk of cerebral
infarction,12 while others suggest that the excess risk is confined
to those individuals with the highest cholesterol levels, generally
within the top 5% of the distribution.33–35 An association between
lower cholesterol and an increased risk of haemorrhagic stroke
has also been reported elsewhere,12,13,30,34,37,38 although not
consistently so.39 While the current analysis provides some
evidence in support of such an inverse association, the results
indicate that the association is comparatively weak, and that the
excess risk of haemorrhagic stroke appears mostly confined to
individuals with the lowest cholesterol levels.
The difference in average baseline cholesterol level between
ANZ and Asian cohorts in the APCSC was approximately 
0.7 mmol/l. While it is important to recognize that these cohorts
are not necessarily representative samples of the populations
CHOLESTEROL, CHD, AND STROKE IN THE ASIA PACIFIC REGION 569
Figure 4 Association between usual cholesterol level and stroke: 
A—any fatal stroke in the entire study population; B—any fatal or non-fatal stroke in the entire study
population; C—any fatal stroke stratified by region; D—any fatal or non-fatal stroke stratified by region. In
Figures 4C and 4D, the hazard ratio for the lowest fifth of cholesterol is fixed at 1.0 separately for Asia and
Australia and New Zealand (ANZ). P-values for test of homogeneity are shown. The number of events
within each fifth of cholesterol is shown separately for Asia and ANZ below Figures 4C and 4D. Analyses are
stratified by study and sex, and adjusted for age at risk, systolic blood pressure, and smoking
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from which they were drawn, this average cholesterol differ-
ence is consistent with data from published cross-sectional
surveys.40–42 The current data suggest that a 0.7-mmol/l
increase in average cholesterol levels in the Asian populations
represented in APCSC could result in an approximate 25–30%
increase in the incidence of CHD, and a 15–20% increase in the
incidence of ischaemic stroke, which would not be counter-
balanced by a possible 10–15% decrease in the incidence of
haemorrhagic stroke. Such predictions are based on changes in
cholesterol levels only, and do not account for the influence of
likely changes in the levels of other cardiovascular risk factors.
Furthermore, as well as increasing the overall mortality due to
CHD and stroke, rising population levels of cholesterol would be
expected to result in a far greater burden of stroke-related
disability. This is especially true since ischaemic stroke, which is
expected to increase both in absolute numbers and relative to
haemorrhagic stroke, has a comparatively lower case-fatality rate.
In summary, this study provides reliable data that indicate
adverse changes in population-wide levels of cholesterol in
many parts of Asia are likely to result in substantial increases in
the incidence of atherothrombotic vascular diseases. The effects
are likely to be similar to those observed during the ‘epidemic’
of cardiovascular diseases observed in most Western countries
several decades ago, with the potential to adversely influence
the health of a large proportion of the global population. Action
to arrest further increases, or preferably to reduce, cholesterol
levels in the Asia-Pacific region is vital.
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Figure 5 Association between usual cholesterol level and stroke subtype: A—fatal ischaemic
stroke; B—fatal or non-fatal ischaemic stroke; C—fatal haemorrhagic stroke; D—fatal or non-fatal
haemorrhagic stroke. Analyses are stratified by study and sex, and adjusted for age at risk, systolic
blood pressure, and smoking
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